Trials / Conditions / Metastatic Hormone Refractory Prostate Cancer
Metastatic Hormone Refractory Prostate Cancer
4 registered clinical trials studyying Metastatic Hormone Refractory Prostate Cancer.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Completed | Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate NCT04477512 | Washington University School of Medicine | Phase 1 |
| Completed | PHA-739358 for Treatment of Hormone Refractory Prostate Cancer NCT00766324 | Nerviano Medical Sciences | Phase 2 |
| Completed | Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001 NCT00636090 | Duke University | — |
| Completed | Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer NCT00411528 | Novartis Pharmaceuticals | Phase 2 |